Barcelona-based pharmaceuticals company Almirall is to acquire one hundred per cent of the share capital of Poli Group Holding, the holding company of Poli Group, which comprises three operating companies – Taurus Pharma, Polichem SA and Polichem Srl.
Poli Group has a diversified and growing portfolio of proprietary and well-established drugs, focused on Dermatology and complemented with a strong portfolio of Gynaecology and Respiratory products, the latter promoted through distributors. The acquired brands include Ciclopoli, the flagship product that has led Poli Group to become a world leader in nail diseases (onychomycosis), a large and underserved market affecting approximately 10-15 per cent of the total population. Other main Dermatology products include Sililevo and Zeloglin, used to treat nail psoriasis and rosacea.
Circa 60 per cent of the product sales of Poli Group, all their activities in R&D and all their direct commercial efforts are in the Dermatology area.
Poli Group’s products are commercialised in 70 countries, with a focus on Europe and Asia. For the last 12 months, ending in June 2015, the company generated net sales close to ~EUR85 million. The company has 85 employees.
Jorge Gallardo, President of Almirall, says: “This important transaction is the result of our continued focus on growing our presence in the global Dermatology market. The products of Poli Group will provide Almirall with leading market positions in key geographies in which we want to increase our footprint. We still have room to grow in Dermatology and will continue to analyse opportunities in the market”.
